Encouraging Momentum on TB R&D:  New TB Drug Regimen Advances to Phase 3 Clinical Trial

April 23th 2014, 4pm EST – Today, the ACTION global health advocacy partnership applauds a new first in tuberculosis (TB) research and development, announced today by TB Alliance and the Bill & Melinda Gates Foundation: The first-ever drug regimen designed to significantly shorten and simplify the treatment of both drug-sensitive and drug-resistant tuberculosis (TB) will advance to a global phase 3 clinical trial, based on positive results from earlier clinical trials.

“Improving the drugs used to treat TB is an urgent mission of medical research,” said Alison Root, ACTION Deputy Director. “This exciting announcement shows the positive progress we are making in TB research and development to replace the outdated and toxic drugs currently used to treat TB.”

The announcement was made earlier today by Bill Gates, co-chair of the Bill & Melinda Gates Foundation. Mr. Gates committed ‘significant funding’ from the Gates Foundation for the next phase of research for the regimen, which is called PaMZ, and issued a call for other donors to also invest in the effort to develop new TB treatments.

Developing new TB drugs has never been more urgent. TB kills 1.3 million people every year, and its drug-resistant strains are evolving quickly. Current TB drug regimens take too long, are complicated to administer, and have harsh side effects. Despite these shortcomings, no new TB drugs have been developed for first line treatment against TB in 50 years.

According to TB Alliance, a not-for-profit organization dedicated to finding faster-acting and affordable drug regimens to fight TB, PaMz shows potential to reduce the time required to treat and cure drug-resistant TB from two years to just a few months. Currently, people with multi drug-resistant TB must stay on treatment for a minimum of 18 to 24 months, taking more than 12,000 pills.

Developing new drugs is a difficult and long-term undertaking, and a phase 3 clinical trial is the final and most expensive stage in the clinical trial process. This encouraging announcement comes at a time when donors are scaling back contributions to TB research and development; globally, TB research and development faces an annual funding gap of $1.4 billion.

“It is crucial that donors like Australia increase their investments in the new technologies needed to reduce regional and global burdens of TB,” said Maree Nutt, CEO of RESULTS International (Australia), an ACTION partner. “With even limited investment, it is clear we are making progress to improve TB treatment. Imagine what can be achieved if our governments collectively step up and ensure TB research and development is fully funded.”

For more information on PaMZ and its upcoming phase 3 clinical trial, visit



ACTION is a global partnership of advocacy organizations working in 10 countries to influence policy to mobilize resources to fight diseases of poverty and improve equitable access to health services.

For more information, or to be connected with our global network of health advocates:
Angela Pereira
Senior Communications Associate
(+1 202) 999-9545